RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > 2022 > 5 > Recon: Moderna announces more than $6B in revenue in first quarter; Valneva to trial booster of its

Recon: Moderna announces more than $6B in revenue in first quarter; Valneva to trial booster of its COVID vaccine

Posted 04 May 2022 | By Joanne S. Eglovitch 

Recon: Moderna announces more than $6B in revenue in first quarter; Valneva to trial booster of its COVID vaccine

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.
In Focus: US
  • AstraZeneca poised to snag fast approval for a frontline use of Imfinzi, adding to its growing oncology portfolio (Endpoints) (AstraZeneca)
  • FDA grants Prothena fast track designation for Alzheimer’s disease therapy (Biopharma Reporter)
  • FDA hits Miami University in Ohio with a warning letter over falsified data (Endpoints) (STAT)
  • FDA Approves Phathom’s Voquezna Triple and Dual PAK (Bloomberg)
  • COVID-19 Vaccines: Spikevax Review Reflected Changing Realities Of Omicron In US (The Pink Sheet)
  • Mifepristone Access Imperiled By Supreme Court’s Draft Decision Overturning Abortion Rights (The Pink Sheet) (Bloomberg)
In Focus: International
  • Vaccines Effective Against New Omicron Variants, WHO Chief Says (Bloomberg)
  • A compromise on patent waivers for Covid-19 vaccines takes a key step at the WTO (STAT)
  • Valneva to launch trial for booster use of its COVID-19 vaccine candidate (Reuters)
  • Novartis' compassionate use requests worldwide: Just 0.5% came from lower-middle- and low-income countries (Endpoints)
  • Australian Regulator On The Highs & Lows Of Project Orbis (Pink Sheet)
  • Biosimilars ‘Policy Salad’ Setting Back Sector, Canadian Study Says (Pink Sheet)
  • Canada Pulls Controversial Pricing Measures (The Pink Sheet)
  • Fresenius warns of bigger Ukraine war impact after Q1 profit beat (Reuters)
  • Regeneron's COVID drug sales outside U.S. help revenue beat (Reuters)
  • COVID worsens asthma in children; booster after infection not as beneficial vs Omicron (Reuters)
  • Pfizer Says Patients Who Relapse After Covid Pill Can Repeat (Bloomberg)
Pharma & Biotech
  • Moderna Highlights More than $6B in Revenue, Talks Boosters (Biospace) (Reuters)
  • Biogen shoves Aduhelm to the side. It’s time for lecanemab (Fierce)
  • All Takeda wants for its billion-dollar gene therapy spending spree is functional cures (Fierce)
  • Chasing Bristol Myers and Pfizer, Connect fails phase 2 ulcerative colitis trial but spies path forward (Fierce)
  • Novartis’ Kisqali Adds Years to Breast Cancer Patients’ Lives (Biospace)
  • Record-breaking 2021 revenue shows there’s more to Swiss biotech sector than Roche, Novartis (Fierce)
  • BMS, Merck KGaA push protein degrader ambitions with $2.3B Amphista partnership (Fierce)
  • An upstart protein degradation contender adds Merck KGaA and Bristol Myers to its list of Big Pharma backers (Endpoints)
  • AstraZeneca’s Alexion to get new Boston headquarters (Biopharma Reporter)
  • Biogen CEO Vounatsos, board and top execs formally agreed to keep the breakup civil (Endpoints)
  • Biden should send ‘clear’ message to semiconductor industry on prioritizing medtech, AdvaMed says (MedTech Dive)
  • Mirvie Granted Breakthrough Device Designation For Test To Identify Risk Of Preeclampsia (MedTech Insight)
Government, Regulatory & Legal
  • HHS Allocates $55 Million for Tribal Opioid Response Program (Bloomberg)
  • Wash. AG, Distributors Cut $518M Deal Ending Opioid Trial (Law360)
  • Opioid Charges Filed by DOJ Against 12 Medical Professionals (Bloomberg)
  • Amazon subsidiary PillPack reaches a settlement with US government and will have to shell out over $5.6M (Endpoints)
Regulatory Recon is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe.
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.


© 2022 Regulatory Affairs Professionals Society.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.